Original Research Article

Effect of apatinib combined with chemotherapy on quality of life and related complications in patients with advanced gastric cancer

Dan Hong¹, Yaning Wei¹, Aimin Zang¹, Zhiyu Wang¹, Lin Yang¹, Guanying Ren¹, Shenyong Su¹, Chong Zhang²*
¹Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, ²Pharmacy Department, Baoding No. 2 Central Hospital, Hebei 072750, PR China
*For correspondence: Email: orenx4@163.com

Sent for review: 16 April 2021 Revised accepted: 27 July 2021

Abstract

Purpose: To investigate the effect of apatinib combined with chemotherapy on quality of life (QOL) and related complications in patients with advanced gastric cancer (AGC).

Methods: Clinical data for 102 AGC patients treated in The Affiliated Hospital of Hebei University (January 2018 - December 2019) were retrospectively analyzed. The subjects were randomly and equally split into chemotherapy group and combination group. Both groups of patients were treated with 180 mg/m² of paclitaxel, and patients in the combination group were additionally given 500 mg of apatinib daily, for a treatment time to disease remission in both groups. Clinical efficacy, QOL, complications as well as serum SIL-2R, VEGF and TNF-α levels in the two groups were compared to analyze the effect of apatinib combined with chemotherapy on AGC patients.

Results: Disease control rate (DCR) and overall response rate (ORR) of gastric cancer patients in the combination group were notably higher than those in the chemotherapy group (p < 0.05). After treatment, the serum SIL-2R, VEGF and TNF-α levels in the two groups decreased significantly, of which the levels in the combination group were clearly lower (p < 0.05). No notable difference in the incidence of complications was observed between the two groups (p > 0.05). After treatment, the QOL scores of both groups increased significantly, of which QOL score in the combination group was notably higher (p < 0.05).

Conclusion: Apatinib combined with chemotherapy effectively enhances the clinical efficacy of AGC patients, controls the overexpression of serum SIL-2R, VEGF and TNF-α, and improves the QOL of patients without increasing adverse reactions. Therefore, the combination therapy is safe and effective.

Keywords: Gastric cancer, Quality of life (QOL), Complications, Apatinib, Chemotherapy

INTRODUCTION

Gastric cancer (GC) is a clinically prevalent gastric malignant tumor with the highest incidence in China, which originates from gastric mucosal epithelial cells. According to statistics, GC is one of the most frequently occurring cancers worldwide, with a five-year survival rate of about 20%. With its incidence tends to...
increase significantly with age, GC occurs mostly in elderly people aged 50-80 years old [1-4].

According to clinical studies, adenocarcinoma is the most common type of GC in clinic. Adenocarcinoma usually has no obvious adverse symptoms in the early stage, or minor symptoms such as abdominal discomfort, which is often mistaken as chronic diseases such as gastric ulcer. Therefore, the early diagnosis of GC in China remains unsatisfactory. In clinical practice, surgery is the most important treatment method for GC, and it is statistically found that the five-year survival rate of early-stage GC treated by surgery reaches 90.9-100%. However, effective treatment methods are needed for advanced gastric cancer (AGC) that is mainly treated with chemotherapy to control tumor growth.

In spite of its significant short-term therapeutic effect, chemotherapy can cause strong side effects, thus leading to unsatisfactory long-term effect. At present, the comprehensive treatment program of small molecule targeted drugs combined with chemotherapy has prominent advantages in the treatment of AGC.

Apatinib is a new small molecule antiangiogenic agent that can change the tumor lesions to vacuoles, especially lesions with abundant blood vessels, thus shrinking the tumor [5-8]. Studies have shown that apatinib with chemotherapy in patients can improve the therapeutic effect, mainly because the addition of apatinib can shrink the tumor faster in some patients whose lesions do not significantly or even not shrink after chemotherapy. Therefore, this paper mainly investigated the clinical effect of apatinib combined with chemotherapy on AGC patients.

METHODS

General information on patients

Clinical data for 102 AGC patients treated in the Affiliated Hospital of Hebei University (January 2018 - December 2019) were retrospectively analyzed. The subjects were randomly and equally split into chemotherapy group and combination group.

Inclusion criteria

Patients who were diagnosed with GC by pathological examination, patients with an expected survival time of at least half a year, and patients with complete clinical medical records were included in the study. The study was approved by the hospital ethics committee, and all the patients and their families accepted the treatment plans and signed the informed consent.

Exclusion criteria

Patients with adverse reactions caused by chemotherapy before the study, patients with contraindication to chemotherapy, patients who were allergic to drugs used in the study, patients complicated with other malignant tumors, and those who were unable to cooperate due to mental or other cognitive disorders, or refused to cooperate with the researchers.

Treatments

After maintenance of water and electrolyte balance and acid-base balance, anti-infective therapy and symptomatic treatment, patients in the chemotherapy group were treated with routine chemotherapy, with 21 days as a chemotherapy cycle. They received 175 mg/m2 of paclitaxel (specification: 30mg, manufacturer: Beijing SL Pharmaceutical Co., Ltd; National Medical Products Administration approval no. H20066640) by intravenous drip 3 hour on the first day of the chemotherapy cycle [9,10]. Timely treatment methods such as venous cannula, arterial cannula or regional perfusion were carried out to patients according to the development of the disease.

In addition to the treatment above, patients in the combination group orally took 500 mg of apatinib (specification: 0.25g; manufacturer: Jiangsu Hengrui Pharmaceutical Co. Ltd; National Medical Products Administration approval no. H20140103) at 30 min after meals, once a day. Apatinib must be taken regularly each day, and could not be supplemented if missed. The dosage should be adjusted according to the doctor’s advice if adverse reactions occurred. Both groups of patients were treated until disease remission.

Observation indices

Response Evaluation Criteria in Solid Tumors (RECIST) was used to evaluate the therapeutic effect of AGC. The tumors disappeared for more than four weeks, which was complete response (CR). Total maximum size of the tumor was reduced by more than 30% and lasted for more than four weeks, which was partial response (PR). The total maximum size of the tumor was reduced by less than 30% or increased by more than 20%, and lasted for more than four weeks, which was stable disease (SD). Total maximum size of the tumor was increased by more than 20%, which was progressive disease (PD).
DCR = \{(CR+PR+SD)/N\}100 ............... (1)

ORR = \{(CR+PR)/N\}100 ..................... (2)

where: DCR = disease control rate of GC; ORR = overall response rate; N = total number of patients; CR = complete response; PR = partial response; and SD = stable disease.

Serum SIL-2R, VEGF and TNF-α levels, and complications were observed. The possible complications included hypertension, gastrointestinal reaction, skin and mucosal reaction, liver function damage, renal impairment, thrombocytopenia, myelosuppression and hemorrhage. Quality of Life (QOL) Assessment Scale designed by the hospital was used to evaluate physical health, mental state, social status, family relationship and sleep quality, and a higher score represented higher QOL of the patients.

Statistical analysis

The data from this study were analyzed by SPSS 20.0 software, including enumeration and measurement data, and subjected to both Chi square and Students t tests. Differences were considered statistically significant when \( p < 0.05 \).

RESULTS

Comparison of general data

No notable differences in general data were found between the two groups \( (p < 0.05) \), see below (Table 1).

Clinical efficacy

Table 2 clearly presented notably higher DCR and ORR of GC in the combination group than the chemotherapy group \( (p < 0.05) \).

Table 1: General clinical profile of patients

| Variable          | Chemotherapy group (n=51) | Combination group (n=51) | t/\( \chi^2 \) | P-value |
|-------------------|---------------------------|--------------------------|---------------|---------|
| Age (years old)   | (53.47±7.52)              | (52.73±7.26)             | 0.5056        | 0.6143  |
| KPS score (points)| (80.21±3.78)              | (81.14±3.67)             | 1.2606        | 0.2104  |
| Differentiation   |                           |                          | 0.0600        | 0.807   |
| Medium            | 10(19.61)                 | 11(21.57)                |               |         |
| Medium-low        | 25(49.02)                 | 26(50.98)                |               |         |
| Low               | 16(31.37)                 | 14(27.45)                |               |         |
| Tumor location    |                           |                          | 0.0393        | 0.843   |
| Cardia and fundus of stomach | 24(47.06)              | 25(49.02)                |               |         |
| Antrum            | 9(17.65)                  | 8(15.69)                 |               |         |
| Gastric body      | 18(35.29)                 | 18(35.29)                |               |         |
| Smoking           |                           |                          | 0.3529        | 0.552   |
| Yes               | 27(52.94)                 | 24(47.06)                |               |         |
| No                | 24(47.06)                 | 27(52.94)                |               |         |
| Drinking          |                           |                          | 0.3671        | 0.545   |
| Yes               | 29(56.86)                 | 32(62.75)                |               |         |
| No                | 22(43.14)                 | 19(37.25)                |               |         |
| Gender            |                           |                          | 0.0448        | 0.832   |
| Male              | 35(68.63)                 | 34(66.67)                |               |         |
| Female            | 16(31.37)                 | 17(33.33)                |               |         |
| Residence         |                           |                          | 0.2065        | 0.650   |
| Urban area        | 37(72.55)                 | 39(76.47)                |               |         |
| Rural area        | 14(27.45)                 | 12(23.53)                |               |         |

Table 2: Comparison of clinical efficacy \( (n \%) \)

| Variable | Chemotherapy group (n=51) | Combination group (n=51) | \( \chi^2 \) | P-value |
|----------|---------------------------|--------------------------|-------------|---------|
| CR       | 0(0)                      | 0(0)                     |             |         |
| PR       | 14(27.45)                 | 26(50.98)                |             |         |
| SD       | 12(23.53)                 | 16(31.37)                |             |         |
| PD       | 25(49.02)                 | 9(17.65)                 |             |         |
| DCR      | 26(50.98)                 | 42(82.35)                | 11.2941     | 0.001   |
| ORR      | 14(27.45)                 | 26(50.98)                | 5.9226      | 0.015   |
Serum SIL-2R, VEGF and TNF-α levels

After treatment, the serum SIL-2R, VEGF and TNF-α levels in the two groups notably decreased, of which the levels in the combination group were obviously lower ($p < 0.05$, Table 3).

Treatment complications

The two groups did not show notable differences in the incidence of complications ($p > 0.05$), as shown in Table 4.

Quality of life

After treatment, the QOL scores of both groups notably increased, of which the QOL score in the combination group was notably higher ($p < 0.05$, Table 5).

DISCUSSION

Gastric cancer (GC) is a malignant tumor in the digestive system with complexes causes. Medical studies have repeatedly proposed that the formation of GC is mostly related to the long-term chronic inflammation associated with gastric mucosal tissue [11-14]. People’s daily diet, work stress, environmental and genetic factors collectively contribute to the increasing incidence of GC in China. Surgical resection of tumors is currently the main treatment to radically eliminate GC in the early and middle stages, but is not suitable for AGC patients. Due to the severe condition, chemotherapy becomes the main treatment method for AGC patients. Soluble interleukin-2 receptor (SIL-2R), an immune active substance and an interleukin receptor, is a cell growth factor in the immune system, which can bind to IL-2 and reduce its activity.

Table 3: Serum SIL-2R, VEGF and TNF-α levels of patients (mean ± SD)

| Index          | Chemotherapy group | Combination Group | t     | P-value |
|----------------|--------------------|-------------------|-------|---------|
| SIL-2R (pmol/L)| Before treatment   | 99.87±18.37       | 100.02±19.29 | 9.5164  | <0.001  |
|                | After treatment    | 79.35±12.48*      | 57.12±11.07*  | 11.2924 | <0.001  |
| VEGF (pg/ml)   | Before treatment   | 262.21±14.97      | 261.85±14.36 | 6.3055  | <0.001  |
|                | After treatment    | 240.55±11.76*     | 215.82±10.31* | 11.2924 | <0.001  |
| TNF-α (g/L)    | Before treatment   | 29.36±8.15        | 29.49±9.23   |         |         |
|                | After treatment    | 25.46±6.14*       | 18.35±5.21*  |         |         |

Note: *$p < 0.05$, vs before treatment within the same group

Table 4: Comparison of complications

| Variable                  | Chemotherapy group | Combination group | $\chi^2$ | P-value |
|---------------------------|--------------------|-------------------|---------|---------|
| Hypertension              | 8(15.38)           | 11(20.75)         | 0.5107  | 0.475   |
| Gastrointestinal reaction | 12(23.08)          | 14(26.42)         | 0.1570  | 0.692   |
| Skin and mucosal reaction | 11(21.15)          | 10(18.87)         | 0.0857  | 0.770   |
| Liver function damage     | 7(13.46)           | 8(15.09)          | 0.0571  | 0.811   |
| Renal impairment          | 2(3.85)            | 3(5.66)           | 0.1905  | 0.663   |
| Thrombocytopenia          | 5(9.62)            | 4(7.55)           | 0.1433  | 0.705   |
| Myelosuppression          | 3(5.77)            | 2(3.77)           | 0.2305  | 0.631   |
| Hemorrhage                | 4(7.69)            | 1(1.89)           | 1.9507  | 0.163   |

Table 5: Comparison of QOL scores

| Group        | Before treatment | After treatment | t      | P-value |
|--------------|------------------|-----------------|--------|---------|
| Chemotherapy | 25.3±3.1         | 37.5±3.6        | 18.3391| <0.001  |
| Combination  | 24.5±3.4         | 42.3±3.2        | 27.2256| <0.001  |
| t            | 7.1168           |                 |        |         |
| $P$-value    |                  |                 | <0.001 |         |
If the serum SIL-2R level increases, the immune response induced by IL-2 will be inhibited, thus reducing the immune function, and creating conditions for the proliferation and infiltration of tumor cells. Abnormal overgrowth of blood vessels around tumors is the leading cause of the deterioration of cancer. VEGF, secreted by tumor cells or stromal cells, plays a key role in the process of abnormal vascular growth. When tumors grow, the function of nutrient vessels is abnormally active and the expression level of VEGF increases sharply. Therefore, targeted therapy for VEGF is carried out in clinic to block the abnormal growth of blood vessels and treat GC [15-17].

TNF-α is a pro-inflammatory cytokine that can participate in normal immune response and inflammatory response, showing a high value under the action of malignant tumors. The mechanism of apatinib, a novel “tyrosine kinase” inhibitor, is mainly that apatinib can specifically bind to ATP sites in recipient cells, block and interfere with ATP phosphorylation, block downstream signal transduction, and thus inhibit tumor angiogenesis. Hiroyuki Ohnuma et al [18] stated in their study that the ORR and DCR of GC patients treated with chemotherapy alone were only 15.4 and 56.4 % while those of patients treated with apatinib combined with chemotherapy were 50 and 84.4 %, indicating that the combination therapy can effectively improve the therapeutic effect in the treatment of GC. Hiroyuki Ohnuma et al’ s finding is consistent with this study showing that the DCR and ORR of GC in the combination group were notably higher compared with the chemotherapy group.

After treatment, serum SIL-2R, VEGF and TNF-α levels in both groups obviously decreased, of which the levels in the combination group were obviously lower, indicating that apatinib combined with chemotherapy can effectively improve the tumor immune function of patients and has a high antagonistic effect on abnormal angiogenesis.

There was no significant difference in the incidence of complications between the two groups, suggesting that apatinib combined with chemotherapy does not increase the physical burden of patients, with safety. After treatment, the life quality scores of both groups were significantly higher than those before treatment, and the scores in the combination group were significantly higher than those in the chemotherapy group, suggesting effectively increased QOL in patients.

Limitations of the study

Patients were followed up for a short time, hence there was a lack of information on the survival time of patients in the later period. In addition, since this research is a single-center study using a small sample size, more multi-center studies with larger sample size are required for the validation of the results in this study.

CONCLUSION

Apatinib combined with chemotherapy effectively enhances the clinical efficacy of AGC patients, controls the overexpression of serum SIL-2R, VEGF and TNF-α, and improves the QOL of patients without increasing adverse reactions. Therefore, the combination therapy is safe and effective.

DECLARATIONS

Acknowledgement

This work was supported by Baoding Science and Technology Support Plan Project (no. 2041ZF293).

Conflict of interest

No conflict of interest is associated with this work.

Contribution of authors

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. DH and YW designed the study and drafted the manuscript. AZ, ZW and LY were responsible for the collection and analysis of the experimental data. GR, SS and CZ revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript. #Dan Hong and Yaning Wei contributed equally to this work.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution,
REFERENCES

1. Roviello G, Ravelli A, Polom K, Petrioli R, Marano L, Marrelli D, Roviello F, Generali D. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett 2016; 372(2): 187-191.

2. Geng R, Song L, Li J, Zhao L. The safety of apatinib for the treatment of gastric cancer. Expert Opin Drug Saf 2018; 17(11): 1145-1150.

3. Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, Yang Y, Li Q. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. J Cancer Res Clin Oncol 2017; 143(2): 361-368.

4. Aoyama T, Yoshikawa T. Targeted therapy: Apatinib-new third-line option for refractory gastric or GEJ cancer. Nat Rev Clin Oncol 2016; 13(5): 268-270.

5. Yang Y, Pei X, Yang M. Combination of apatinib and continuous nutritional support for a gastric cancer patient with brain metastasis prolongs survival. J Clin Pharm Ther 2018; 43(5): 726-729.

6. Zhang Y, Gou M, Han C, Li J, Wang L, Qiao Q, Hu Y, Bai L, Liu Z. Efficacy and safety of apatinib as second-line therapy for advanced gastric cancer: a single-center observational study. Anticancer Drugs 2018; 29(2): 184-189.

7. Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, Zhang G, Zhao C, Zhang Y, Chen C, et al. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. Clin Cancer Res 2019; 25(2): 515-523.

8. Ma JL, Zhang T, Suo FZ, Chang J, Wan XB, Feng XJ, Zheng YC, Liu HM. Lysine-specific demethylase 1 activation by vitamin B2 attenuates efficacy of apatinib for proliferation and migration of gastric cancer cell MGC-803. J Cell Biochem 2018; 119(6): 4957-4966.

9. de Mello RA, de Oliveira J, Antoniou G. Angiogenesis and apatinib: a new hope for patients with advanced gastric cancer? Future Oncol 2017; 13(4): 295-298.

10. Cheng X, Feng H, Wu H, Jin Z, Shen X, Kuan J, Huo Z, Chen X, Gao H, Ye F, et al. Targeting autophagy enhances apatinib-induced apoptosis via endoplasmic reticulum stress for human colorectal cancer. Cancer Lett 2018; 431: 105-114.

11. Zhu XR, Zhu ML, Wang Q, Xue WJ, Wang YW, Wang RF, Chen SY, Zheng LZ. A case report of targeted therapy with apatinib in a patient with advanced gastric cancer and high serum level of alpha-fetoprotein. Medicine (Baltimore) 2016; 95(37): e4610.

12. Yang Y, Wu N, Shen J, Teixido C, Sun X, Lin Z, Qian X, Zou Z, Guan W, Yu L, et al. MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer. Gastric Cancer 2016; 19(3): 778-788.

13. Wang Y, Bi M, Zhang H, Gao Z, Zhou H, Chang S. Apatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease. Asia Pac J Clin Oncol 2017; 13(5): e528-e530.

14. Pu Z, Wang Y, Ge F, Zhu S, Cheng Y, Liu H, et al. Matrine induces cell cycle arrest and apoptosis in hepatocellular carcinoma cells via miR-122 mediated CG1/livin/survivin signal axis. Trop J Pharm Res 2021; 20(2): 263-268.

15. Kishi K, Fujiwara Y, Yano M, Motoori M, Sugimura K, Takahashi H, Ohue M, Sakon M. Usefulness of diagnostic laparoscopy with 5-aminolevulinic acid (ALA)-mediated photodynamic diagnosis for the detection of peritoneal micrometastasis in advanced gastric cancer after chemotherapy. Surg Today 2016; 46(12): 1427-1434.

16. Takahari D. Second-line chemotherapy for patients with advanced gastric cancer. Gastric Cancer 2017; 20(3): 395-406.

17. Namikawa T, Tsuda S, Fujisawa K, Iwabu J, Uemura S, Tsujii S, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K. Conversion surgery after S-1 plus oxaliplatin combination chemotherapy for advanced gastric cancer with multiple liver metastases. Clin J Gastroenterol 2018; 11(4): 297-301.

18. Ohnuma H, Sato Y, Hirakawa M, Kikuchi S, Miyashi K, Sagawa T, Takahashi Y, Nobuoka T, Okamoto K, Miyamoto H, et al. Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study. Cancer Chemother Pharmacol 2018; 81(3): 539-548.